Faron's proprietary precision immunotherapy, Bexmarilimab, has the ability to target myeloid cell function and provide long-lasting immune stimulation for challenging cancer types.
Faron's proprietary precision immunotherapy, Bexmarilimab, has the ability to target myeloid cell function and provide long-lasting immune stimulation for challenging cancer types.
